Patents by Inventor Gregory John Carven

Gregory John Carven has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1
    Publication number: 20210403560
    Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
    Type: Application
    Filed: September 8, 2021
    Publication date: December 30, 2021
    Applicant: Merck Sharp & Dohme B.V.
    Inventors: Gregory John Carven, Hans van Eenennaam, Gradus Johannes Dulos
  • Antibodies to human programmed death receptor PD-1
    Patent number: 11117961
    Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: September 14, 2021
    Inventors: Gregory John Carven, Hans van Eenennaam, Gradus Johannes Dulos
  • ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1
    Publication number: 20180111996
    Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
    Type: Application
    Filed: November 13, 2017
    Publication date: April 26, 2018
    Applicant: Merck Sharp & Dohme B.V.
    Inventors: Gregory John Carven, Hans van Eenennaam, Gradus Johannes Dulos
  • Antibodies to human programmed death receptor PD-1
    Patent number: 9834605
    Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 5, 2017
    Assignee: Merck Sharpe & Dohme B.V.
    Inventors: Gregory John Carven, Hans Van Eenenneem, Gradus Johannes Dulos
  • ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1
    Publication number: 20160304606
    Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
    Type: Application
    Filed: December 19, 2014
    Publication date: October 20, 2016
    Applicant: MERCK SHARP & DOHME B.V.
    Inventors: Gregory John Carven, Hans Van Eenenneem, Gradus Johannes Dulos
  • ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1
    Publication number: 20150232555
    Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
    Type: Application
    Filed: December 19, 2014
    Publication date: August 20, 2015
    Applicant: MERCK SHARP & DOHME B.V.
    Inventors: Gregory John Carven, Hans Van Eenenneem, Gradus Johannes Dulos
  • Antibodies to human programmed death receptor PD-1
    Patent number: 8952136
    Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: February 10, 2015
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Gregory John Carven, Hans Van Eenenneem, Gradus Johannes Dulos
  • Antibodies to human programmed death receptor PD-1
    Patent number: 8900587
    Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 2, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gregory John Carven, Hans Van Eenenneem, Gradus Johannes Dulos
  • Antibodies to human programmed death receptor PD-1
    Patent number: 8354509
    Abstract: Antibodies which block the binding of human Programmed Death Receptor 1 (hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: January 15, 2013
    Assignee: MSD Oss B.V.
    Inventors: Gregory John Carven, Hans van Eenennaam, Gradus Johannes Dulos
  • ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1
    Publication number: 20100266617
    Abstract: Antibodies which block the binding of human Programmed Death Receptor 1(hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.
    Type: Application
    Filed: June 13, 2008
    Publication date: October 21, 2010
    Inventors: Gregory John Carven, Hans Van Eenennaam, Gradus Johannes Dulos